Distribution of SALT scores by therapeutic response in patients with severe alopecia after 52 weeks of baricitinib therapy

Natasha Mesinkovska1, Maryanne Senna2, Arash Mostaghiim3, Julien Seneschal4, Amy McMichael5, Najwa Soman6, Na Lu7, Jianxiang Zou4, Jakub Jedynak8, Hitoe Torisu-Itakura9, Jerry Shapiro9

1University of California, Irvine, Irvine, CA, USA; 2Lahey Hospital and Medical Center, and Harvard Medical School Boston, MA, USA; 3Brigham and Women’s Hospital, Boston, MA, USA; 4University Hospital Bordeaux, Bordeaux, France; 5Wake Forest School of Medicine, Winston-Salem, NC, USA; 6Eli Lilly and Company, Indianapolis, IN, USA; 7Precision Statistics Consulting, Woodbury, MN, USA; 8TechData Services, Prussia, PA, USA
9Department of Dermatology, New York University School of Medicine, New York, NY, USA

OBJECTIVE
To report the distribution of SALT scores across the spectrum of therapeutic response in patients with severe alopecia areata (AA) who were treated with baricitinib in the BRAVE-AA1 and BRAVE-AA2 clinical trials.

BACKGROUND
Baricitinib is an oral selective JAK inhibitor that has demonstrated efficacy versus placebo to regrow scalp hair, eyebrows, and eyelashes in patients with severe AA in the phase 3 trials BRAVE-AA1 and -AA2.1,2

The safety profile across indications including rheumatoid arthritis, atopic dermatitis, and AA, is well-characterized.3

Clinical trial response criteria were defined as achievement of SALT score ≤20 (80% scalp coverage) by weeks 36 and 52. However, the distribution of absolute SALT scores across patients who do not meet this response threshold have not been described.

The treatment benefit and distribution of SALT scores at Week 52 across the spectrum of responders are reported here.

RESULTS
Distribution of SALT scores over time with treatment (ITT population)

A) Over half of patients achieved improved* SALT scores at Week 52 regardless of baseline severity

B) Proportion of patients achieving each SALT score subcategory at Week 52 by baseline disease severity

Proportion of patients achieving Eyebrow/Eyelash regrowth* by dose and by scalp response

CONCLUSIONS
While a significant proportion of patients treated with baricitinib 2 mg and 4 mg achieved clinically meaningful response goal of SALT ≤20 (80% scalp coverage), a substantial proportion of additional patients demonstrated movement towards improvement.

Proportion of patients improved from baseline SALT category was higher among those with lower baseline severity.

Patients across the treatment spectrum demonstrated clinically meaningful regrowth of eyebrows and eyelashes.

These data provide a broader view of patient responses among baricitinib-treated patients with severe AA.

Disclosure: N. Mesinkovska has provided professional services for: AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Concert Pharmaceuticals, Eli Lilly and Company, La Roche-Posay, and Pfizer. M. Senna has served on advisory boards and/or has been a consultant for: Arena Pharmaceuticals, Concert Pharmaceuticals, Eli Lilly and Company, and Pfizer; and is a clinical trial investigator for: Concert Pharmaceuticals and Eli Lilly and Company. A. Mostaghiim has been a consultant for: AbbVie, ASLAN Pharmaceuticals, Concert Pharmaceuticals, Digital Diagnostics, Eli Lilly and Company, Equillium, Hims & Hirs Health, and Pfizer; J. Seneschal has received consulting fees from: AbbVie, LEO Pharma, Eli Lilly and Company, Novartis, Sanofi-Genzyme, Pierre Fabre, and Pfizer; A. McMichael has received grants/research support from: AbbVie and/or has been a consultant for: Allergan, Almirall, Cosmeceutica Pharmaceuticals, Concert Pharmaceuticals, Eli Lilly and Company, Galderma, Inopey Cooperation, Pfizer, Procter & Gamble, and Renen; N. Soman; J. Jedynak; and H. Torisu-Itakura are employees and shareholders of Eli Lilly and Company. M. Lu is an employee of Precision Statistics Consulting. J. Zou is an employee of TechData Services; J. Shapiro is a consultant and/or clinical trial investigator for Pfizer and is a consultant for Eli Lilly and Company.

References

Abbreviations: AA-severe alopecia; AT-severe alopecia total; BARI-baricitinib; ClinRO E/E-Clinician-Reported Outcomes for Eyebrow; ClinRO EL-Clinician-Reported Outcomes for Eyelash; ITT-intention-to-treat; IQR-interquartile range; Jak-Janus kinase; SALT-Score of Alopecia Tool

Fall Clinical Dermatology Conference (Fall CDC 2023); Las Vegas, USA; 19-22 October 2023

This study was sponsored by Eli Lilly and Company, under license from Incyte Corporation